Zambia Pharmaceutical and Healthcare Markets Analyzed in New In-Demand BMI Report Published at

21 Jan 2013 • by Natalie Aster

LONDON – Notwithstanding a relatively high incidence of some serious diseases (e.g. HIV/Aids, tuberculoses, malaria and malnutrition), Zambia suffers from severe shortage educated medical stuff as well as specialist diagnostic and treatment centres, laboratories and pharmaceutical supply. The largest portion of investment in the local healthcare sector comes from aids agencies playing on the worldwide medical arena since the country’s government cannot allocate huge sums to the sector.

The pharmaceutical expenditure was approximately USD 195 million in 2011 and slightly over USD 206 million in 2012 in the country. Meantime, the domestic healthcare expenditure was estimated USD 1.1 billion in 2011 and almost reached USD 1.2 billion a year later.

New market research report “Zambia Pharmaceuticals and Healthcare Report Q1 2013” developed by Business Monitor International (BMI) provides access to a 360 degree view of pharmaceutical and healthcare markets in Zambia. The study offers a detailed review of the industries, besides offering valuable data on pharmaceutical risk/reward ratings, regulatory regime and the key growth factors. A detailed description of possible development trends of the markets in the years to come and demographic outlook can be found in the study, as well.

Report Details:

Zambia Pharmaceuticals and Healthcare Report Q1 2013
Published: January, 2013
Pages: 41
Price: US$ 1,175.00

More Q1 2013 Country Market Research Reports by BMI are Also Available:

More new research reports by the publishers can be found at BMI page.


MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970